Oral cyclic melphalan and dexamethasone for patients with al amyloidosis

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 6, 2010, Pages 469-472

  Sanchorawala, Vaishali ^a,b   Seldin, David C ^a,b   Berk, John L ^b   Sloan, J Mark ^a,b   Doros, Gheorghe ^c   Skinner, Martha ^b  

^a Section of Hematology/Oncology   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Heart failure; Oral treatment; Stem cell transplantation

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN;

ADULT; AGED; AMYLOID LIGHT CHAIN AMYLOIDOSIS; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CORTICOSTEROID INDUCED MYOPATHY; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME;

EID: 79952918063     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.081     Document Type: Article

References (11)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349:583-96. (Pubitemid 36951371)
2. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996; 100:290-8. (Pubitemid 26111626)
3. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336:1202-7. (Pubitemid 27183649)
4. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med 2004; 140:85-93.
5. Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of hematologic response on out come of patients undergoing transplantation for primary amyloidosis: Importance of achieving a complete response. Haematologica 2007; 92:1415-8. (Pubitemid 350144161)
6. Sanchorawala V, Skinner M, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007; 110:3561-3. (Pubitemid 350159622)
7. Sanchorawala V, Seldin DC. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid 2007; 14:261-9. (Pubitemid 350035577)
8. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357:1083-93. (Pubitemid 47443213)
9. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103:2936-8. (Pubitemid 38451663)
10. Lebovic D, Hoffman J, Levine BM, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008; 143:369-73.
11. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 2010; 11:29-37.